製品番号: HY-N0381

Maackiain

Name: Maackiain
Brand: MedChemExpress
SKU: HY-N0381
Price: 37.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(別名: DL-Maackiain)

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Maackiain (DL-Maackiain) is an orally active multi-target inhibitor with anti-tumor activity and neuroprotective effects. Maackiain activates the AMPK, NLRP3 and Nrf2/HO-1 pathways, and inhibits key targets such as NF-κB, mTOR, MAO-B, NFATc1 and PKCδ, thereby precisely regulating processes including apoptosis, autophagy and pyroptosis. Maackiain also effectively inhibits microglial activation, osteoclast formation, and proliferation and invasion of tumor cells, and protects dopaminergic neurons from damage. Maackiain is applicable to the research of various diseases such as Alzheimer's disease, osteoporosis, sepsis and dengue fever。

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.83%
CAS 番号: 19908-48-6
分子式: C₁₆H₁₂O₅
分子量:284.27

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Maackiain 構造式

CAS 番号: 19908-48-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

HY-N0616
Trifolirhizin

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (1)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

p38 MAP kinase

PKCδ

MAO-B

NLRP3

p38 MAPK アイソフォーム固有の製品をすべて表示 :

NOD-like Receptor (NLR) アイソフォーム固有の製品をすべて表示 :

NF-κB アイソフォーム固有の製品をすべて表示 :

mTOR アイソフォーム固有の製品をすべて表示 :

Monoamine Oxidase アイソフォーム固有の製品をすべて表示 :

MAO-A
MAO-B

PKC アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-15	IC₅₀	>25 μg/mL Compound: 6	Cytotoxicity against human HCT15 cells by MTT assay Cytotoxicity against human HCT15 cells by MTT assay	[PMID: 17764956]
HL-60	IC₅₀	17.9 μg/mL Compound: 6	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 17764956]
HMC1	IC₅₀	3.01 μM Compound: 9	Inhibition of A23187-induced IL-6 production in human HMC1 cells incubated for 30 mins prior to A23187 challenge measured after 24 hrs by ELISA Inhibition of A23187-induced IL-6 production in human HMC1 cells incubated for 30 mins prior to A23187 challenge measured after 24 hrs by ELISA	[PMID: 25467151]
MDA-MB-435	IC₅₀	11.5 μg/mL Compound: 6	Cytotoxicity against human MDA-MB-435 cells by MTT assay Cytotoxicity against human MDA-MB-435 cells by MTT assay	[PMID: 17764956]
RAW264.7	IC₅₀	27 μM Compound: 2	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25592708]
U-937	IC₅₀	>100 μM Compound: 19, l-maackiain	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	>100 μM Compound: 19, l-maackiain	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	>100 μM Compound: 19, l-maackiain	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 17158054]

体外実験

Maackiain exhibits no direct bactericidal or bacteriostatic activity against Escherichia coli, Enterobacter cloacae, or Staphylococcus aureus^[1].
Maackiain (10-100 ng/mL; pre-incubated for 30 min; co-incubated with LPS for 24 h) inhibits LPS-induced production of proinflammatory cytokines IL-1β, IL-6 and TNF-α in RAW264.7 cells in a dose-dependent manner, suppresses LPS-induced nuclear translocation of NF-κB p65 in RAW264.7 cells, and attenuates oxidative stress by reducing ROS generation, restoring mitochondrial membrane potential, and reversing the levels of GSH, MDA and TEAC^[1].
Maackiain (100 ng/mL; pre-incubated for 3 h following pretreatment with AMPK/Nrf2 inhibitors, then co-incubated with LPS for 24 h) exerts antioxidant and anti-inflammatory activities in RAW264.7 cells by activating the AMPK/Nrf2/HO-1 pathway^[1].
Maackiain (10-50 μM; 6 h) dose-dependently inhibits Aβ42 (10 μM; 24 h)-induced apoptosis, oxidative stress, inflammatory response, cellular damage and loss of viability in PC12 cells; it also promotes nuclear translocation of Nrf2 in PC12 cells without altering the total expression of Nrf2^[2].
Maackiain (5-40 μM; 5 days) dose-dependently inhibits RANKL-induced osteoclast formation in mouse bone marrow macrophages, and at the dose of 40 μM, disrupts the formation of functional F-actin belts in mature mouse osteoclasts^[3].
Maackiain (20-40 μM; 5 days) downregulates the expression of key genes associated with osteoclast differentiation and function in RANKL-stimulated mouse bone marrow macrophages^[3].
Maackiain (40 μM; 1-5 days) suppresses the expression of osteoclast-specific proteins c-Fos, Integrin β3, MMP9, CTSK and NFATc1 in RANKL-stimulated mouse bone marrow macrophages; meanwhile, it downregulates the protein level of NFATc1 and inhibits its nuclear translocation^[3].
Maackiain (40 μM; 1 h) blocks IκB-α degradation and p65 phosphorylation, inhibits RANKL-induced activation of the NF-κB pathway in mouse bone marrow-derived macrophages, and thereby attenuates RANKL-induced calcium oscillations in mouse bone marrow-derived macrophages^[3].
Maackiain (50-100 ng/mL; sequential treatment for 1 h after 3 h of LPS pre-treatment and 1 h of incubation with 5 μM nigericin (HY-127019)) enhances 5 μM nigericin-induced caspase-1 activation and mature IL-1β production in LPS-pretreated human monocytic cell line dTHP-1, and exhibits a dose-dependent effect at concentrations of 50 ng/mL and 100 ng/mL^[4].
Maackiain (2.5-40 μM; 24 h after LPS incubation) potently inhibits NO production in LPS-stimulated BV2 microglia, with the strongest effect observed at 20 μM, and exhibits a concentration-dependent response at concentrations below 20 μM^[5].
Maackiain (10-40 μM; 24 h after LPS incubation) potently inhibits LPS-induced lipid peroxidation in BV2 microglial cells, and the antioxidant activity at the dose of 40 μM is stronger than that of Ferrostatin-1^[5].
Maackiain (100 ng/mL; 24 h) inhibits the proliferation of human cervical cancer HeLa and SiHa cells in a concentration-dependent manner, induces autophagy (elevated expression levels of LC3-II and Beclin-1, autophagosome formation) in human cervical cancer HeLa and SiHa cells, and induces cell apoptosis^[6].
Maackiain (75 μM; 3 days) induces DNA fragmentation and apoptotic body formation in human promyelocytic leukemia HL-60 cells, and this effect is inhibited by pretreatment with the antioxidant N-acetyl-L-cysteine (5 mM; 2 h pre-incubation)^[7].
(-)-maackiain (50-150 μM; 24 h) inhibits the upregulation of IL-4 mRNA in IgE/antigen-induced RBL-2H3 cells, whereas the synthetic (+)-maackiain exerts no significant inhibitory activity^[8].
(-)-Maackiain (20, 40 μM; 24 h) inhibits PMA-induced phosphorylation of Tyr311 on PKCδ in HeLa cells^[8].
(-)-Maackiain (30 μM; 24 h) inhibits phorbol 12-myristate 13-acetate (PMA)-induced translocation of protein kinase Cδ (PKCδ) to the Golgi apparatus in HeLa cells^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

RAW264.7 mouse macrophage cells
Concentration:

10-300 ng/ml
Incubation Time:

24 h
Result:

Showed no obvious effect on cell viability at 10, 50, or 100 ng/ml. Slightly decreased cell viability at 300 ng/ml.

Western Blot Analysis^[1]

Cell Line:

RAW264.7 mouse macrophage cells
Concentration:

100 ng/ml (time-dependent assay); 10-100 ng/ml (dose-dependent assay)
Incubation Time:

3-24 h (time-dependent assay; 100 ng/ml); 24 h (dose-dependent assay; 10-100 ng/ml)
Result:

Increased nuclear Nrf2 levels (elevated at 3 h, peaked at 12 h), decreased cytoplasmic Nrf2 levels, increased HO-1 levels, and increased p-AMPKα levels in a time-dependent manner at 100 ng/ml. Increased nuclear Nrf2 levels, decreased cytoplasmic Nrf2 levels, increased HO-1 levels, and increased p-AMPKα levels in a dose-dependent manner at 10, 50, 100 ng/ml for 24 h.

Cell Viability Assay^[2]

Cell Line:

rat pheochromocytoma PC12 cells
Concentration:

10-50 μM
Incubation Time:

6 h (pretreatment); 24 h (Aβ42 exposure)
Result:

Increased cell viability relative to Aβ42-only treated cells. Decreased LDH activity relative to Aβ42-only treated cells. Showed statistically significant dose-dependent protective effects at all tested concentrations.

Apoptosis Analysis^[2]

Cell Line:

rat pheochromocytoma PC12 cells
Concentration:

10-50 μM
Incubation Time:

6 h (pretreatment); 24 h (Aβ42 exposure)
Result:

Decreased TUNEL-positive cell counts relative to Aβ42-only treated cells. Reduced caspase-3 activity relative to Aβ42-only treated cells. Showed statistically significant dose-dependent anti-apoptotic effects at all tested concentrations.

Western Blot Analysis^[4]

Cell Line:

LPS-primed differentiated THP-1 (dTHP-1) human monocyte cells
Concentration:

50-100 ng/mL
Incubation Time:

1 h (sequential treatment after 3 h LPS priming and 1 h 5 μM nigericin incubation)
Result:

Amplified nigericin-induced cleavage of pro-caspase-1 to its active p20 subunit and pro-IL-1β to mature IL-1β, with a dose-dependent effect at 50 and 100 ng/mL. Did not alter LPS-induced pro-IL-1β production when used alone with LPS. Significantly increased mature IL-1β release when combined with nigericin.

Western Blot Analysis^[4]

Cell Line:

MPL-primed dTHP-1 human monocyte cells
Concentration:

100 ng/mL
Incubation Time:

1 h (sequential treatment after 3 h MPL priming and 1 h nigericin incubation at 1 or 2 μM)
Result:

Amplified nigericin-induced cleavage of pro-caspase-1 to p20 and mature IL-1β production in MPL-primed cells, even at reduced nigericin concentrations (1 or 2 μM). Did not increase IL-1β release relative to MPL priming alone when used alone.

Apoptosis Analysis^[6]

Cell Line:

human cervical cancer HeLa cells, human cervical cancer SiHa cells
Concentration:

0-100 μM (alone); 50 μM (combined with cisplatin)
Incubation Time:

24 h
Result:

Induced apoptosis in HeLa and SiHa cells in a concentration-dependent manner at 50, 100 μM, increasing the percentage of apoptotic cells and upregulating expression of cleaved PARP1, cleaved Caspase 3, cleaved Caspase 7, and cleaved Caspase 9. Enhanced cisplatin-induced apoptosis and apoptotic protein expression when used in combination at 50 μM.

Western Blot Analysis^[6]

Cell Line:

human cervical cancer HeLa cells, human cervical cancer SiHa cells
Concentration:

0-100 μM
Incubation Time:

24 h
Result:

Increased phosphorylated AMPK (p-AMPK) levels in a concentration-dependent manner. Decreased phosphorylated mTOR (p-mTOR), phosphorylated p70 S6K (p-p70 S6K), and phosphorylated 4E-BP1 (p-4E-BP1) levels in a concentration-dependent manner. Had no effect on total AMPK, mTOR, p70 S6K, 4E-BP1, ACC, or phosphorylated ACC (p-ACC) levels.

Real Time qPCR^[8]

Cell Line:

HeLa cells
Concentration:

10-30 μM (purified (-)-maackiain); 10, 30 μM (synthesized (-)-maackiain, synthesized (+)-maackiain)
Incubation Time:

24 h (pre-incubation)
Result:

Significantly suppressed PMA-induced H1R mRNA elevation at all tested concentrations (purified (-)-maackiain). Significantly suppressed PMA-induced H1R mRNA elevation at 30 μM (synthesized (-)-maackiain). Significantly suppressed PMA-induced H1R mRNA elevation at 10 and 30 μM (synthesized (+)-maackiain).

体内実験

Maackiain (2.5-5 mg/kg; i.p.; single dose 12 hours pre-CLP) protects against CLP-induced sepsis in mice via dose-dependent reductions in mortality, organ injury, systemic inflammation, and oxidative stress, with the 5 mg/kg dose reducing 7-day mortality to 40%^[1].
Maackiain (25-50 mg/kg; i.g.; daily; 14 days) improves LPS-induced cognitive impairment, increases normal neuron counts, inhibits microglial activation, and reduces cortical pro-inflammatory mediator levels in male C57BL/6 mice, with the 50 mg/kg dose demonstrating superior efficacy in most metrics^[5].
Maackiain (5 mg/kg; i.p.; once every 2 days; 6 total injections) reduces cervical tumor weight to ~40% of control levels and inhibits tumor growth by 50% relative to controls without causing significant systemic toxicity in nude mice^[6].
Racemic maackiain (5-20 mg/kg; p.o.; daily; 21 days) alleviates TDI-induced allergic rhinitis symptoms and suppresses TDI-induced upregulation of H1R and IL-4 gene expression in Brown Norway rats, with significant effects observed at doses of 5, 10, and 20 mg/kg administered orally daily for 21 days^[8].
Maackiain (10-50 μg/mL; immersion; single exposure) demonstrates potent larvicidal activity against Aedes aegypti 4th instar larvae, with an LC₅₀ of 21.95 ± 1.34 μg/mL at 48 hours^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57/BL6 (6-week-old male)^[1]
Dosage:

2.5 mg/kg; 5 mg/kg
Administration:

i.p.; single dose 12 hours pre-CLP
Result:

Reduced 7-day mortality rate from ~90% to 60% (2.5 mg/kg) and to 40% (5 mg/kg).\nImproved clinical scores of CLP-induced septic mice in a dose-dependent manner.\n
Significantly alleviated CLP-induced pathological lesions in the lung, liver, spleen, and kidney.\nReduced serum levels of inflammatory cytokines IL-1β, IL-6, and TNF-α in a dose-dependent manner at 12 and 24 hours post-CLP.\n
Reversed CLP-induced reductions in serum GSH levels and Trolox Equivalent Antioxidant Capacity (TEAC), and reversed CLP-induced increases in serum malondialdehyde (MDA) levels in a dose-dependent manner.\n
Abrogated Maackiain-induced reductions in serum IL-1β, IL-6, and TNF-α levels at 12 and 24 hours post-CLP when pre-treated with Compound C or ML385.\n
Reversed Maackiain-induced improvements in serum GSH levels, TEAC, and MDA levels when pre-treated with Compound C or ML385.\n
Reduced the survival rate of Maackiain-treated septic mice, worsened their clinical scores, and diminished Maackiain's protective effects against CLP-induced organ injury when pre-treated with Compound C or ML385.

Animal Model:

C57BL/6 (male, 7-8 weeks old, 18-22 grams, SPF-grade)^[5]
Dosage:

25 mg/kg; 50 mg/kg
Administration:

i.g.; daily; 14 days
Result:

Significantly reduced escape latency in the Morris Water Maze training phase compared to the LPS group.
Increased the time mice spent in the target quadrant during the probe trial and increased platform crossings at 50 mg/kg dose; showed no significant difference in these probe trial metrics vs the LPS group at 25 mg/kg dose.\n
Increased the number of normal neurons in the hippocampus at 50 mg/kg dose, and increased the number of normal neurons in the cortex at 25 mg/kg dose, both compared to the LPS group.\n
Reduced IBA-1 fluorescence intensity (a marker of microglial activation) in brain tissue compared to the LPS group at both doses, with the 50 mg/kg dose showing a greater inhibitory effect than the 25 mg/kg dose.\n
Reduced COX-2 expression in the cortex compared to the LPS group at both doses, with the 50 mg/kg dose showing the strongest inhibitory effect.\n
Reduced IL-6 expression in the cortex compared to the LPS group at both doses, with the 50 mg/kg dose showing a greater inhibitory effect; no significant differences in hippocampal IL-6 levels were observed between either maackiain dose group and the LPS group.

Animal Model:

nude mice (4-week-old, unspecified gender)^[6]
Dosage:

5 mg/kg
Administration:

i.p.; once every 2 days; 6 total injections
Result:

Reduced mean tumor volume to ~700 mm³ (control ~1400 mm3) 21 days after first treatment.\n
Reduced mean tumor weight to ~40% of control levels.\n
Caused no significant changes in mouse body weight.\n
Showed no toxicity to the heart, kidney, or liver via hematoxylin and eosin staining.

Animal Model:

Brown Norway rats (6-week-old male, 200-250 g, allergic rhinitis model via TDI sensitization and challenge)^[8]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

p.o.; daily; 21 days
Result:

Significantly reduced the number of sneezes and suppressed TDI-induced upregulation of IL-4 mRNA in nasal mucosa (5 mg/kg).\n
Significantly reduced the number of sneezes, suppressed TDI-induced upregulation of IL-4 mRNA in nasal mucosa, and showed a trend toward reducing nasal scores (10 mg/kg).\n
Significantly reduced the number of sneezes, reduced nasal scores, and suppressed TDI-induced upregulation of both H1R and IL-4 mRNA in nasal mucosa (20 mg/kg).

Animal Model:

Rockefeller (4th instar larvae)^[9]
Dosage:

10, 20, 30, 35, 40, 50 μg/mL
Administration:

immersion; single exposure
Result:

Exhibited larvicidal activity with a 48-hour LC₅₀ value of 21.95 μg/mL, with a 95% confidence interval of 19.27-24.46 μg/mL.

化学情報

CAS 番号 19908-48-6
性状 Solid
分子量 284.27
分子式 C₁₆H₁₂O₅
Color White to off-white
SMILES

OC1=CC=C2OC[C@]3([H])C4=CC5=C(OCO5)C=C4O[C@]3([H])C2=C1
別名

DL-Maackiain
Structure Classification
- Phenols
- Monophenols
- Others
Initial Source
- Plants
- other families
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

J Pharm Biomed Anal

Identification of new small molecule inhibitors of PD-1/PD-L1 interaction by a comprehensive ligand fishing system. [Abstract]

2026 Mar 15:270:117281. PMID: 41308584

溶剤 & 溶解度

体外:

DMSO : 250 mg/mL (879.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5178 mL

17.5889 mL

35.1778 mL

5 mM

0.7036 mL

3.5178 mL

7.0356 mL

10 mM

0.3518 mL

1.7589 mL

3.5178 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 50 mg/mL (175.89 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (305 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Bai X, et al. Maackiain protects against sepsis via activating AMPK/Nrf2/HO-1 pathway. Int Immunopharmacol. 2022;108:108710. [Content Brief]

[2]. Lu N, et al. Maackiain Prevents Amyloid-Beta-Induced Cellular Injury via Priming PKC-Nrf2 Pathway. Biomed Res Int. 2022;2022:4243210. Published 2022 Jun 22. [Content Brief]

[3]. Liu Y, et al. Maackiain dampens osteoclastogenesis via attenuating RANKL-stimulated NF-κB signalling pathway and NFATc1 activity. J Cell Mol Med. 2020;24(21):12308-12317. [Content Brief]

[4]. Huh JW, et al. Maackiain, a compound derived from Sophora flavescens, increases IL-1β production by amplifying nigericin-mediated inflammasome activation. FEBS Open Bio. 2020;10(8):1482-1491. [Content Brief]

[5]. Yun T, et al. Maackiain Reduces Neuroinflammation by Modulating Inflammatory Signals in LPS-Induced In Vitro and In Vivo Models. J Microbiol Biotechnol. 2026;36:e2508046. Published 2026 Feb 5. [Content Brief]

[6]. He J, et al. Maackiain suppresses the development of cervical cancer via AMPK priming autophagy. J Pharm Pharmacol. 2024;76(1):23-33. [Content Brief]

[7]. Aratanechemuge Y, et al. Induction of apoptosis by maackiain and trifolirhizin (maackiain glycoside) isolated from sanzukon (Sophora Subprostrate Chen et T. Chen) in human promyelotic leukemia HL-60 cells. Oncol Rep. 2004 Dec;12(6):1183-8. [Content Brief]

[8]. Mizuguchi H, et al. Maackiain is a novel antiallergic compound that suppresses transcriptional upregulation of the histamine H1 receptor and interleukin-4 genes. Pharmacol Res Perspect. 2015;3(5):e00166. [Content Brief]

[9]. Bezerra-Silva PC, et al. Extract of Bowdichia virgilioides and maackiain as larvicidal agent against Aedes aegypti mosquito. Exp Parasitol. 2015;153:160-164. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5178 mL	17.5889 mL	35.1778 mL	87.9446 mL
	5 mM	0.7036 mL	3.5178 mL	7.0356 mL	17.5889 mL
	10 mM	0.3518 mL	1.7589 mL	3.5178 mL	8.7945 mL
	15 mM	0.2345 mL	1.1726 mL	2.3452 mL	5.8630 mL
	20 mM	0.1759 mL	0.8794 mL	1.7589 mL	4.3972 mL
	25 mM	0.1407 mL	0.7036 mL	1.4071 mL	3.5178 mL
	30 mM	0.1173 mL	0.5863 mL	1.1726 mL	2.9315 mL
	40 mM	0.0879 mL	0.4397 mL	0.8794 mL	2.1986 mL
	50 mM	0.0704 mL	0.3518 mL	0.7036 mL	1.7589 mL
	60 mM	0.0586 mL	0.2931 mL	0.5863 mL	1.4657 mL
	80 mM	0.0440 mL	0.2199 mL	0.4397 mL	1.0993 mL
	100 mM	0.0352 mL	0.1759 mL	0.3518 mL	0.8794 mL

Bioz

Maackiain

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Maackiain

MedChemExpress（MCE）の使用を引用している文献 Maackiain

p38 MAPK アイソフォーム固有の製品をすべて表示

NOD-like Receptor (NLR) アイソフォーム固有の製品をすべて表示

NF-κB アイソフォーム固有の製品をすべて表示

mTOR アイソフォーム固有の製品をすべて表示

Monoamine Oxidase アイソフォーム固有の製品をすべて表示

PKC アイソフォーム固有の製品をすべて表示

生物活性